Revenue Breakdown
Composition ()
No data
Revenue Streams
Fennec Pharmaceuticals Inc (FENC) generates its revenue primarily from PEDMARK product sales, which accounts for 100.0% of total sales, equivalent to $7.26M. Understanding this concentration is critical for investors evaluating how FENC navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Fennec Pharmaceuticals Inc maintains a gross margin of 94.70%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1.52%, while the net margin is -5.12%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively FENC converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, FENC competes directly with industry leaders such as AKBA and ACIU. With a market capitalization of $270.50M, it holds a significant position in the sector. When comparing efficiency, FENC's gross margin of 94.70% stands against AKBA's 81.66% and ACIU's 100.00%. Such benchmarking helps identify whether Fennec Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
